// App-Quantinova.ai

BSH2020‐PO‐119 : Feasibility and safety of 90‐min rapid rate daratumumab in myeloma: a prospective multicentre observational study

Researchers

Presenter

  • N. Maouche

Principal Investigators

  • J. Allan

  • L. Thompson

  • L. Wignall

  • C. Parbutt

  • R. Senior

  • V. Macgregor

  • A. Atkinson

  • J. Collini

  • J. Skelly

  • E. Goodwin

  • E. Portman

  • F. Djebbari

  • K. Ramasamy

Medical Centers

  • Dept of Haematology, Oxford University Hospitals NHS Foundation Trust

  • Department of Pharmacy, NHS Greater Glasgow and Clyde, Glasgow

  • Rheumatology, University Hospital Southampton NHS Foundation Trust, Southampton, UNITED KINGDOM

  • Medicines Management and Pharmacy Services, The Leeds Teaching Hospitals NHS Trust, Leeds

  • Department of Pharmacy, Aberdeen Royal Infirmary, NHS Grampian, Aberdeen

  • Department of Cardiology, University Hospital of Wales, Cardiff, UK

  • Department of Pharmacy, North West Anglia NHS Foundation Trust, Huntington, UK

Locations

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Multiple Myeloma

Biomarkers

  • Cluster of Differentiation 38

Drug/Treatment

  • Chlorphenamine

  • Dexamethasone

  • Dekpak 13 Day Taperpak

  • Lenalidomide

  • Prednisolone

  • daratumumab Intravenous

  • Montelukast

  • Acetaminophen

  • Bortezomib

Outcome

  • N/A

Study Design

  • Observational

  • Multicenteric

  • Prospective

  • Single Center

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved